Interim Clinical Commissioning Policy: Thrombopoietin receptor agonists as first line therapy for new or relapsed immune thrombocytopenia in adults and children over the age of 1 year during the COVID-19 pandemic,NHS England,updated 6th October 2021

The policy is for thrombopoietin receptor agonists as first line therapy for new or relapsed acute immune thrombocytopenia in adults and children over the age of 1 year.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news